Rash from EGFR inhibitors: Opportunities and challenges for palliation

Benjamin M. Solomon, Aminah Jatoi

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.

Original languageEnglish (US)
Pages (from-to)304-308
Number of pages5
JournalCurrent oncology reports
Volume10
Issue number4
DOIs
StatePublished - Dec 1 2008

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this